These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24986638)

  • 1. A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment.
    Drago A; Cocchi E; Crisafulli C; Serretti A
    J Neural Transm (Vienna); 2015 Mar; 122(3):465-75. PubMed ID: 24986638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genomewide association study of citalopram response in major depressive disorder.
    Garriock HA; Kraft JB; Shyn SI; Peters EJ; Yokoyama JS; Jenkins GD; Reinalda MS; Slager SL; McGrath PJ; Hamilton SP
    Biol Psychiatry; 2010 Jan; 67(2):133-8. PubMed ID: 19846067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.
    Perlis RH; Purcell S; Fava M; Fagerness J; Rush AJ; Trivedi MH; Smoller JW
    Arch Gen Psychiatry; 2007 Jun; 64(6):689-97. PubMed ID: 17548750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.
    Binder EB; Owens MJ; Liu W; Deveau TC; Rush AJ; Trivedi MH; Fava M; Bradley B; Ressler KJ; Nemeroff CB
    Arch Gen Psychiatry; 2010 Apr; 67(4):369-79. PubMed ID: 20368512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.
    Shiroma PR; Drews MS; Geske JR; Mrazek DA
    Am J Geriatr Psychiatry; 2014 Nov; 22(11):1140-8. PubMed ID: 23973251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder.
    Garriock HA; Tanowitz M; Kraft JB; Dang VC; Peters EJ; Jenkins GD; Reinalda MS; McGrath PJ; von Zastrow M; Slager SL; Hamilton SP
    Am J Psychiatry; 2010 May; 167(5):565-73. PubMed ID: 20194481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.
    Cutler JA; Rush AJ; McMahon FJ; Laje G
    J Psychopharmacol; 2012 Mar; 26(3):360-7. PubMed ID: 22282879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.
    Rush AJ; Bernstein IH; Trivedi MH; Carmody TJ; Wisniewski S; Mundt JC; Shores-Wilson K; Biggs MM; Woo A; Nierenberg AA; Fava M
    Biol Psychiatry; 2006 Mar; 59(6):493-501. PubMed ID: 16199008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.
    Nierenberg AA; Husain MM; Trivedi MH; Fava M; Warden D; Wisniewski SR; Miyahara S; Rush AJ
    Psychol Med; 2010 Jan; 40(1):41-50. PubMed ID: 19460188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
    Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
    Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial.
    Salardini E; Zeinoddini A; Mohammadinejad P; Khodaie-Ardakani MR; Zahraei N; Zeinoddini A; Akhondzadeh S
    J Psychiatr Res; 2016 Apr; 75():24-30. PubMed ID: 26800392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.
    ; ;
    Am J Psychiatry; 2013 Feb; 170(2):207-17. PubMed ID: 23377640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.
    Rush AJ; Wisniewski SR; Zisook S; Fava M; Sung SC; Haley CL; Chan HN; Gilmer WS; Warden D; Nierenberg AA; Balasubramani GK; Gaynes BN; Trivedi MH; Hollon SD
    Psychol Med; 2012 Jun; 42(6):1131-49. PubMed ID: 22008447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and drug induced side effects in early versus late antidepressant responders.
    Fabbri C; Marsano A; Balestri M; De Ronchi D; Serretti A
    J Psychiatr Res; 2013 Oct; 47(10):1309-18. PubMed ID: 23800418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.
    Fabbri C; Crisafulli C; Calati R; Albani D; Forloni G; Calabrò M; Martines R; Kasper S; Zohar J; Juven-Wetzler A; Souery D; Montgomery S; Mendlewicz J; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2017 Dec; 267(8):723-735. PubMed ID: 28260126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy.
    Arias B; Fabbri C; Serretti A; Drago A; Mitjans M; Gastó C; Catalán R; Fañanás L
    J Affect Disord; 2014 Oct; 168():91-7. PubMed ID: 25043320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trajectories of individual symptoms in remitters versus non-remitters with depression.
    Sakurai H; Uchida H; Abe T; Nakajima S; Suzuki T; Pollock BG; Sato Y; Mimura M
    J Affect Disord; 2013 Nov; 151(2):506-513. PubMed ID: 23886402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of Life and Functioning in Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder After Treatment With Citalopram Monotherapy.
    Steiner AJ; Boulos N; Mirocha J; Wright SM; Collison KL; IsHak WW
    Clin Neuropharmacol; 2017; 40(1):16-23. PubMed ID: 27764051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans.
    Dong C; Wong ML; Licinio J
    Mol Psychiatry; 2009 Dec; 14(12):1105-18. PubMed ID: 19844206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study.
    Brown ES; Vigil L; Khan DA; Liggin JD; Carmody TJ; Rush AJ
    Biol Psychiatry; 2005 Dec; 58(11):865-70. PubMed ID: 15993860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.